Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_3
1
33%
Ph phase_4
1
33%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_4

Selenium Supplementation in Youths With Autoimmune Thyroiditis

NCT02644707
completedphase_3

S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate

NCT00030901
completednot_applicable

Selenium Treatment in Autoimmune Thyroiditis (AIT)

NCT00271427

Clinical Trials (3)

Showing 3 of 3 trials
NCT02644707Phase 4

Selenium Supplementation in Youths With Autoimmune Thyroiditis

Completed
NCT00030901Phase 3

S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate

Completed
NCT00271427Not Applicable

Selenium Treatment in Autoimmune Thyroiditis (AIT)

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3